Brattström D, Bergqvist M, Lamberg K, Kraaz W, Scheibenflug L, Gustafsson G, Inganäs M, Wagenius G, Brodin O
Department of Oncology, Uppsala Akademiska Hospital, Uppsala University, Sweden.
Med Oncol. 1998 Dec;15(4):255-61. doi: 10.1007/BF02787209.
In this study the entire p53 complementary DNA has been sequenced in 20 non-small cell lung carcinomas (NSCLC) and the results correlated with chemosensitivity, immunohistochemistry and clinical data. Ten patients had mutations in p53, 8 missense mutations and 2 nonsense mutations. The method discovered two mutations never described previously and two other mutations that have never been described before in connection with NSCLC tumours. Chemosensitivity data, according to a short-term assay (FMCA), indicated that tumours with p53 mutation were more resistant to cisplatin and cyclophosphamide. Immunohistochemical studied demonstrated a 70% concordance between over-expression of p53 protein and mutation in p53. No conclusions or trends could be drawn from the immunohistochemical studies of Bcl-2 and Bax.
在本研究中，对20例非小细胞肺癌（NSCLC）的整个p53互补DNA进行了测序，并将结果与化学敏感性、免疫组织化学及临床数据相关联。10例患者的p53存在突变，8例为错义突变，2例为无义突变。该方法发现了两个此前从未描述过的突变以及另外两个从未在NSCLC肿瘤中描述过的与p53相关的突变。根据短期检测法（FMCA）得到的化学敏感性数据表明，p53突变的肿瘤对顺铂和环磷酰胺更具抗性。免疫组织化学研究显示，p53蛋白过表达与p53突变之间的一致性为70%。对Bcl-2和Bax的免疫组织化学研究未得出任何结论或趋势。
